stoxline Quote Chart Rank Option Currency Glossary
Innoviva, Inc. (INVA)
15.35  0.01 (0.07%)    05-30 16:00
Open: 15.4
High: 15.48
Volume: 302,222
Pre. Close: 15.34
Low: 15.32
Market Cap: 959(M)
Technical analysis
2024-05-30 4:42:22 PM
Short term     
Mid term     
Targets 6-month :  18.57 1-year :  19.29
Resists First :  15.9 Second :  16.52
Pivot price 15.81
Supports First :  14.89 Second :  12.39
MAs MA(5) :  15.56 MA(20) :  15.71
MA(100) :  15.48 MA(250) :  14.29
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  18.6 D(3) :  30.3
RSI RSI(14): 44.7
52-week High :  16.86 Low :  12.22
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ INVA ] has closed above bottom band by 12.4%. Bollinger Bands are 19.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 15.52 - 15.62 15.62 - 15.71
Low: 15.06 - 15.19 15.19 - 15.32
Close: 15.15 - 15.35 15.35 - 15.54
Company Description

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Headline News

Thu, 30 May 2024
Principal Financial Group Inc. Sells 7607 Shares of Innoviva, Inc. (NASDAQ:INVA) - Defense World

Thu, 30 May 2024
Innoviva, Inc. (NASDAQ:INVA) Shares Sold by Teacher Retirement System of Texas - Defense World

Thu, 30 May 2024
BNP Paribas Financial Markets Buys 26980 Shares of Innoviva, Inc. (NASDAQ:INVA) - Defense World

Wed, 29 May 2024
Moving Average Crossover Alert: Innoviva - Yahoo Movies UK

Tue, 28 May 2024
Innoviva, Inc. (NASDAQ:INVA) Stake Boosted by Charles Schwab Investment Management Inc. - MarketBeat

Tue, 28 May 2024
Is Innoviva (INVA) a Great Value Stock Right Now? - Yahoo Movies Canada

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 62 (M)
Shares Float 51 (M)
Held by Insiders 0.9 (%)
Held by Institutions 117.5 (%)
Shares Short 11,350 (K)
Shares Short P.Month 11,330 (K)
Stock Financials
EPS 2.24
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 11.14
Profit Margin 58.2 %
Operating Margin 33.2 %
Return on Assets (ttm) 7.1 %
Return on Equity (ttm) 28.6 %
Qtrly Rev. Growth 1.5 %
Gross Profit (p.s.) 0
Sales Per Share 4.99
EBITDA (p.s.) 2.8
Qtrly Earnings Growth 9.8 %
Operating Cash Flow 152 (M)
Levered Free Cash Flow 131 (M)
Stock Valuations
PE Ratio 6.85
PEG Ratio 0.9
Price to Book value 1.37
Price to Sales 3.07
Price to Cash Flow 6.28
Stock Dividends
Dividend 0.25
Forward Dividend 0
Dividend Yield 1.6%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android